Recent researches suggest that there may be a relationship between neurohormones, immune status and cancer. The observations, on the basis of which this experiment was undertaken, run briefly as follows: tumour onset has been shown to be associated with changes in neuroendocrine functions. These include brain neurotransmitter concentrations (Vinnitsky, 1988) , pineal activity and opioid peptide secretion . Melatonin (MLT) represents the best understood hormone produced by the pineal gland, and it has a particular importance in the modulation of brain neurotransmitter pathways (Anton-Tay et al., 1968) . MLT, therefore, has been proposed as a means of monitoring the neuroendocrine status during cancer development (Ebels, 1980) . Several experimental observations have shown that both the pineal hormone MLT (Buswell, 1975) and endogenous opioid peptides (Morley et al., 1985) may influence cancer growth by regulating cell proliferation and immune reactions. In particular, MLT has been seen to induce the expression of interleukin-2 (IL-2) receptors on immune cells (Cattaneo et al., 1988) and to synergise with IL-2 in the generation of LAK cells in some conditions (Maestroni et al., 1988) . Because of the well documented importance of IL-2 in the activation of an effective antitumour immune response (Grimm et al., 1982) Table I. This study accords with the in vitro results previously reported by other authors (Nakayama et al., 1983) , would suggest that metastatic dissemination may be associated with a reduced IL-2 secretion in human solid neoplasms. The mechanisms responsible for the decreased IL-2 production in cancer have still to be understood. Since recent experimental observations have showed that IL-2 secretion is influenced by a neuroendocrine control, it is not possible to exclude that the low IL-2 production in cancer may depend, at least in part, on alterations in the psychoneuroendocrine control of the immunity. Moreover, the results of this study show that an increased MLT secretion is associated with higher levels of IL-2 in respect to those found in patients, who do not show any hyperfunction of the pineal gland; this finding would suggest that the enhanced MLT secretion may counteract tumour growth by modulating host anti-tumour biological response. However, the associations between high levels of MLT and of IL-2 are not necessarily representative of a causative link. In vitro studies to test the effects of MLT on IL-2-dependent immune response will be required to better understand the role of the pineal hormone and to verify whether MLT may directly influence or not IL-2 production and activity. Our preliminary in vitro data would suggest a stimulatory role of MLT on some IL-2-dependent immune reactions (Cattaneo et al., 1988) . Moreover, it has to be remarked that the present study was limited to the detection of the only daily levels of the pineal hormone. Therefore, further studies will be needed to better define which relation Correspondence: P. Lissoni. Received 2 January 1990; and in revised form 24 April 1990. exists between MLT and IL-2 secretions in cancer patients
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